2019年冠状病毒病(COVID-19)的全球大流行是由严重急性呼吸道综合症冠状病毒-2(SARS-CoV-2)引起的。截至2022年11月2日,世界卫生组织(世卫组织)收到628,035,553起报告的COVID-19事件,死亡人数为6,572,800人,截至2022年10月31日,已经交付了12,850,970,971剂疫苗。感染可引起肺部的轻度或自限性症状,严重感染或死亡可能是由SARS-CoV-2感染引起的。同时,抗病毒药物,皮质类固醇,免疫治疗,抗生素,抗凝剂已被提议作为治愈COVID-19感染患者的潜在药物。在这些初始治疗中,COVID-19恢复期血浆(CCP),从COVID-19康复的患者中回收,用作被动免疫疗法,将治愈患者的抗体给予感染患者以预防疾病。这种治疗在疾病的预防或早期阶段的早期产生了最好的结果。恢复期血浆(CP)是最初出现传染病时的第一种治疗方法,尽管很少进行随机对照试验(RCT)来评估其有效性.历史记录表明,对其他呼吸道感染有潜在益处,如严重急性呼吸系统综合症-CoV-I(SARS-CoV-I)和中东呼吸综合症(MERS)等冠状病毒,尽管对此类研究的分析受到一些非随机实验(NRE)的限制。随着流行病的即时性,以下方面对CP的严格研究提出了更高的要求,CP的使用可能会限制将其用于临床测试的能力,产品的非同质性质,高度分散的制造过程;生物功能测量能力的限制,替代疗法的最终可用性,作为抗病毒药物,纯化的免疫球蛋白,或单克隆抗体。不过,目前尚不清楚CCP在住院COVID-19患者中的作用效果如何.当前的审查试图将重点放在其在临床场景中的效率和使用上,并确定在大流行期间实施的现有好处或它如何帮助未来的大流行预防。
Worldwide pandemic with coronavirus disease-2019 (COVID-19) was caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). As November 2, 2022, World Health Organization (WHO) received 628,035,553 reported incidents on COVID-19, with 6,572,800 mortalities and, with a total 12,850,970,971 vaccine doses have been delivered as of October 31, 2022. The infection can cause mild or self-limiting symptoms of pulmonary and severe infections or death may be caused by SARS-CoV-2 infection. Simultaneously, antivirals, corticosteroids, immunological treatments, antibiotics, and anticoagulants have been proposed as potential medicines to cure COVID-19 affected patients. Among these initial treatments, COVID-19 convalescent plasma (
CCP), which was retrieved from COVID-19 recovered patients to be used as passive immune therapy, in which antibodies from cured patients were given to infected patients to prevent illness. Such treatment has yielded the best results in earlier with preventative or early stages of illness. Convalescent plasma (CP) is the first treatment available when infectious disease initially appears, although few randomized controlled trials (RCTs) were conducted to evaluate its effectiveness. The historical record suggests with potential benefit for other respiratory infections, as coronaviruses like Severe Acute Respiratory Syndrome-CoV-I (SARS-CoV-I) and Middle Eastern Respiratory Syndrome (MERS), though the analysis of such research is constrained by some non-randomized experiments (NREs). Rigorous studies on CP are made more demanding by the following with the immediacy of the epidemics, CP use may restrict the ability to utilize it for clinical testing, non-homogenous nature of product, highly decentralized manufacturing process; constraints with capacity to measure biologic function, ultimate availability of substitute therapies, as antivirals, purified immune globulins, or monoclonal antibodies. Though, it is still not clear how effectively
CCP works among hospitalized COVID-19 patients. The current review tries to focus on its efficiency and usage in clinical scenarios and identifying existing benefits of implementation during pandemic or how it may assist with future pandemic preventions.